Self-administered interventions for anogenital warts in immunocompetent patients: a systematic review and meta-analysis
- 1 November 2016
- journal article
- review article
- Published by BMJ in Sexually Transmitted Infections
- Vol. 93 (3), 155-161
- https://doi.org/10.1136/sextrans-2016-052768
Abstract
Background Anogenital warts (AGWs, condylomata acuminata) are among the most common STIs and may severely impact quality of life (QoL). Available treatment options are characterised by a high proportion of non-responders and recurrences. Objective To systematically review and meta-analyse the available evidence from randomised controlled trials (RCTs) on topical treatments for AGWs considering short-term and long-term efficacy, effects on QoL and adverse events (AE). Methods A comprehensive literature search was performed in Cochrane Central Register of Controlled Trials, Embase and MEDLINE. Included studies were evaluated with the Cochrane Collaboration's risk of bias tool. The confidence in the pooled effect estimates was evaluated according to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach and categorised as ‘very low’, ‘low’, ‘moderate’ or ‘high’. Results Eighteen RCTs met the inclusion criteria. Regarding complete clearance (CC), imiquimod 3.75% and 5% cream, podophyllotoxin 0.5% solution and gel and polyphenon E 10% and 15% ointment were superior to placebo. Although more local AE and pain occurred in the actively treated groups, differences regarding dropouts due to AE were not statistically significant. For podophyllotoxin 0.15% cream, no placebo-controlled trials were available; however, in an active-controlled trial, it was inferior to podophyllotoxin 0.5% solution with respect to CC. No significant differences were detected between imiquimod 5% cream and podophyllotoxin 0.5% solution and between polyphenon E 10% and 15% ointment. No data on the influence on health-related QoL were available. Conclusion Our confidence in the pooled estimates (GRADE quality of the evidence) ranged from very low to high. Apart from the given results, other aspects such as availability, costs or patient preference have to be considered when making a treatment choice. Due to the limited number of direct comparisons, conclusions on the relative efficacy of the different treatment options are restricted.Keywords
This publication has 26 references indexed in Scilit:
- GRADE guidelines 6. Rating the quality of evidence—imprecisionJournal of Clinical Epidemiology, 2011
- GRADE guidelines: 7. Rating the quality of evidence—inconsistencyJournal of Clinical Epidemiology, 2011
- GRADE guidelines: 9. Rating up the quality of evidenceJournal of Clinical Epidemiology, 2011
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- Imiquimod 3.75% Cream Applied Daily to Treat Anogenital Warts: Combined Results from Women in Two Randomized, Placebo-Controlled StudiesInfectious Diseases in Obstetrics and Gynecology, 2011
- GRADE guidelines: 4. Rating the quality of evidence-study limitations (risk of bias)Journal of Clinical Epidemiology, 2011
- Efficacy and Safety of Imiquimod Versus Podophyllotoxin in the Treatment of Anogenital WartsSexually Transmitted Diseases, 2011
- Sinecatechins, a Defined Green Tea Extract, in the Treatment of External Anogenital WartsObstetrics & Gynecology, 2008
- Topical Polyphenon®E in the treatment of external genital and perianal warts: a randomized controlled trialBritish Journal of Dermatology, 2008
- A randomized, double‐blind, four‐arm parallel‐group, placebo‐controlled Phase II/III study to investigate the clinical efficacy of two galenic formulations of Polyphenon® E in the treatment of external genital wartsJournal of the European Academy of Dermatology and Venereology, 2007